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Abstract
A 30-year-old woman with a history of smoking presented with abdominal pain and haematuria.
On physical examination, she had a palpable pelvic mass. Imaging revealed a large pelvic mass
located on the dome of the bladder, extending from the urachus, with pulmonary metastases. After
open biopsy, urachal adenocarcinoma was histologically confirmed. The patient received six cycles
of palliative chemotherapy combination 5 fluorouracil and irinotecan with complete response on
the pelvic mass and partial response estimated to more than 80% on pulmonary metastasis.
Introduction
Primary adenocarcinomas of the bladder and urachus are
extremely rare, accounting for 0.5-2.0% of all bladder
malignancies. Although single-institution series have sug-
gested that urachal adenocarcinomas account for 25-30%
of primary adenocarcinomas of the bladder, a recent pop-
ulation-based analysis indicated that urachal adenocarci-
nomas represent approximately 10% of this group [1].
The urachus is a musculofibrous band that extends from
the dome of the bladder to the umbilicus. During fetal
development, the urachus develops into the median
umbilical ligament that stretches from the umbilicus to
the bladder. Urachal carcinoma stems from the epithe-
lium of the remnant of this structure and adenocarcinoma
accounts for 90% of all cases. Pathological examination of
specimens of urachal carcinoma can reveal fragments of
adenocarcinoma that float within 'pools' or 'lakes' of
mucin (Figure 1). Patients with urachal carcinoma most
commonly present with dysuria, hematuria, abdominal
pain, or umbilical discharge [2]. The diagnostic evalua-
tion for urachal carcinoma should include a careful his-
tory and physical examination. An urinalysis with
cytology may be helpful. CT or MRI scans of the abdomen
and pelvis can provide information on local extent of the
disease, pelvic lymph-node involvement, and liver metas-
tases. A cystoscopy is necessary to evaluate whether the
carcinoma has penetrated the urothelium of the bladder
and a transurethral biopsy should be performed if possi-
ble. To evaluate the presence of metastatic disease in the
lungs or bone, chest X-rays and/or bone scans should be
obtained. The MD Anderson Cancer Center has developed
practical criteria for the diagnosis of urachal cancer and
Sheldon et al. has proposed a staging schema for urachal
carcinomas [3]. While early stage tumors are localized
within the urachal mucosa, advancedstage lesions can
extend into local structures such as the bladder, abdomi-
nal wall or peritoneum, and metastases to regional lymph
nodes or distant sites [2]. A staging schema proposed by
investigators at the Mayo Clinic highly correlated to the
staging system proposed by Sheldon et al. and was advo-
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[4].
Case peresentation
A 30-year-old Moroccan woman presented to her primary
care physician having experienced abdominal pain, dysu-
ria, and episodic gross hematuria for 1 month. Her medi-
cal history was unexceptional except for a 10-pack-year
smoking history. Physical examination revealed a palpa-
ble suprapubic pelvic mass. The rest of her examination
including pelvic and complete lymph-node examinations
was unremarkable. Initial laboratory tests were all nor-
mal. An MRI of the abdomen and pelvis obtained 3
months after surgery revealed a lobulated left pelvic mass
measuring 7.8 × 6.6 cm in the area of the prior pelvic-side-
wall mass (Figure 2). No obvious sites of distant metas-
tases were noted. A chest CT scan revealed a multiple
pulmonary metastasis (Figure 3) and bone scan were neg-
ative. The patient underwent a cystoscopy, which revealed
an indentation at the dome of the bladder and normal
mucosa, biopsy was performed. The histological examina-
tion showed a poorly differentiated carcinoma to areas
with poorly differentiated 'signet-ring' cells (Figure 1A). In
addition, the tumor had a mucinous appearance with
nests of neoplastic cells floating in pools of extracellular
mucin (Figure 1B). Immunohistochemical staining
revealed that these pleomorphic cells were positive for
cytokeratin 20 but negative for calretinin consistent with
metastatic carcinoma. A diagnosis of urachal carcinoma
with locoregional extension to the left pelvic wall was
made. The patient began chemotherapy 2 weeks after the
MRI with irinotecan at 240 mg/m2/day 1, bolus 5-fluor-
ouracil (5-FU) at 350 mg/m2, and leucovorin at 25 mg/
m2/day 1 to day 5, delivered every 3 weeks. Owing to sig-
nificant diarrhea, the chemotherapy dose was reduced by
25% after the first cycle and the patient tolerated this dose
for the subsequent cycles. MRI of the abdomen and pelvis
performed after 6 cycles of chemotherapy revealed no evi-
dence of disease (Figure 4). At the last follow-up, no new
sites of metastatic disease were noted on imaging scans.
Discussion
Primary treatment of potentially localized disease
includes wide local excision of the urachus, umbilicus,
and surrounding soft tissue combined with partial or rad-
ical cystectomy and bilateral pelvic lymphadenectomy
[4,5]. Although radical cystectomy has historically been
advocated, several studies have demonstrated long-term
survival with extended partial cystectomy including en
bloc removal of the umbilicus, urachal tumor mass, the
Histological examination of the tumorFigure 1
Histological examination of the tumor. (A) Sheets of 
poorly differentiated 'signet-ring' cells (arrows). (B) Nests of 
neoplastic cells floating in pools of extracellular mucin.
MRI showing the extent of disease before therapy: Cross-sectional view of lobula ed left pelvic mass measuring 7.8 × 6.6 cmFigure 2
MRI showing the extent of disease before therapy: 
Cross-sectional view of lobulated left pelvic mass 
measuring 7.8 × 6.6 cm.Page 2 of 4
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Despite primary treatment, a retrospective analysis of 66
patients with primary urachal carcinoma treated at the
Mayo Clinic revealed a 5-year overall survival rate of only
49% [4,6,7]. Risk factors for recurrence include lack of en
bloc resection of the umbilicus, peritoneal involvement,
and positive nodes and/or margins [4,6,8]. Owing to lack
of early symptoms, the cancer usually presents at an
advanced stage. In a population-based study including 62
individuals with a primary diagnosis of urachal tumor,
only one patient had cancer localized to the urachus [5].
Rates of local recurrence are high, with disease usually
reoccurring in the pelvis or bladder within 2 years of sur-
gery [2,6]. Chemotherapy and radiation for urachal aden-
ocarcinoma have resulted in minimal responses with no
definitive improvement in survival. The rarity of the can-
cer has prevented accrual to controlled clinical trials. Case
reports describe results with various 5-FU and/or cispla-
tin-based regimens [9-12]. Despite measurable responses
to treatment, tumors often recur and the majority of
patients die within 2 years of diagnosis. Siefker-Radtke et
al. Reported the results of a retrospective review of 42
patients treated at the MD Anderson Cancer Center.
Among the 26 patients who developed metastases, only 4
had significant responses to chemotherapy, and of the 9
patients who received chemotherapy with 5-FU or cispla-
tin-containing regimens three responded [6]. A phase II
trial with 5-FU, leucovorin, cisplatin, and gemcitabine for
adenocarcinomas of the urachus is ongoing at the MD
Anderson Cancer Center [3]. Irinotecan is a topoisomer-
ase I inhibitor that disrupts cell division by interfering
with DNA replication. Irinotecan has demonstrated pre-
clinical activity in adenocarcinomas from a variety of
tumor types including gastric, colorectal, pancreatic, lung
and breast carcinomas [13]. Currently, irinotecan in com-
bination with 5-FU/leucovorin with or without bevacizu-
mab is indicated as first-line therapy for metastatic
colorectal cancer [14]. Irinotecan has also demonstrated
efficacy for metastatic gastric cancer in combination with
5-FU/leucovorin or cisplatin [15,16]. Urachal adenocarci-
nomas are often histologically similar to adenocarcino-
mas at other sites of origin, including those in then
gastrointestinal tract such as the colon or stomach. The
histology from this patient demonstrated the typical 'sig-
net-ring' pattern that is also typical of gastric cancer. There
is an additional case study in the literature from Japan that
describes a patient with metastatic urachal carcinoma and
a history of considerable chemotherapy whose lung
lesions had a marked response to irinotecan.
Conclusion
Currently, there is no standard chemotherapy regimen for
the treatment of metastatic urachal adenocarcinoma. The
demonstration that more recently developed agents have
efficacy in adenocarcinomas from other tumor types
should inspire treatment options for this difficult disease.
In addition, agents that demonstrate efficacy in metastatic
disease should be pursued in trials designed to clarify the
role of neoadjuvant or adjuvant chemotherapy in urachal
adenocarcinoma.
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CT scan view of pulmonary metastasisFigure 3
CT scan view of pulmonary metastasis.
MRI showing the extent of disease after therapy: Resolution of the left pelvic mass after ch motherapyFigure 4
MRI showing the extent of disease after therapy: Res-
olution of the left pelvic mass after chemotherapy.Page 3 of 4
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